Osteopenia and osteoporosis among treatment-experienced people living with HIV

Lara, Bárbara Marques de Castro; Pádua, Cristiane Menezes de; Mendicino, Cássia Cristina Pinto; Rocha, Gustavo Machado

doi:10.1016/j.bjid.2020.05.008

Cited by 6 publications

(2 citation statements)

References 43 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a meta-analysis, Goh et al reported that there was a 2-fold increased risk of osteopenia/osteoporosis in PLWH undergoing an ART regimen as compared with the control group 33 . Lara et al reported that bone mineral changes were detected in 47.8% of the patients in their study of 92 PLWH 34 . Clinical studies show that the use of tenofovir in particular is associated with this condition 35,36 .…”

Section: Discussionmentioning

confidence: 90%

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV

Ergen¹,

Bektaş²,

Aydın³

et al. 2022

Afr H. Sci.

View full text Add to dashboard Cite

Background: People living with HIV need to use antiretroviral therapy throughout their lives. Objectives: Studies on the efficacy and safety of dual therapy are limited in Turkey. We sought to evaluate the treatment efficacy and side effects among patients who were given a combination of dolutegravir (DTG) and lamivudine (3TC) as a maintenance therapy. Methods: This retrospective, single-centre study included individuals with viral suppression who were older than 18 years of age, living with HIV, switched from a combination antiretroviral therapy regimen to DTG-3TC dual therapy, and followed up for at least 6 months. Results: The study included 63 patients living with HIV. The median age was 42 years (interquartile range (IQR): 36-51 years). The median follow-up under the DTG-3TC regimen was 10.4 months (7.1-16.0 months). In the course of dual therapy, no patients developed any serious adverse effects that would necessitate a therapy switch, but virological blips were seen in two patients. Two patients lost their lives, with one dying from suicide and one dying from respiratory failure associated with the underlying chronic obstructive pulmonary disease. Conclusion: The DTG-3TC dual-therapy regimen is a promising and effective therapy that can be used as a treatment of choice for eligible patients. Keywords: Dolutegravir; lamivudine; dual; antiretroviral therapy; efficacy.

show abstract

Section: Discussionmentioning

confidence: 90%

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV

Ergen¹,

Bektaş²,

Aydın³

et al. 2022

Afr H. Sci.

View full text Add to dashboard Cite

show abstract

“…En Sudamérica, dos estudios que incluían alrededor del 70% de su muestra a pacientes varones de todas las edades, encontraron una prevalencia entre el 23 al 27% de baja masa ósea (Da Silva et al, 2017). Sólo en uno de ellos, el uso de nevirapina y tenofovir/emtricitabina se asoció con disminución de la masa ósea La pérdida de DMO es sustancial durante los primeros 2 años del TAR, disminuyendo entre 2 al 6% (Marques et al, 2020). Todos los grupos de antirretrovirales se han asociado con pérdida de masa ósea; pero los medicamentos con mayor influencia parecen ser los inhibidores de la proteasa y los inhibidores de la transcriptasa inversa análogos de nucleósidos (Gullón & García, 2013).…”

Section: Introductionunclassified

Low Bone Mineral Density in Young Men With Asymptomatic Human Immunodeficiency Virus Infection on Antiretroviral Therapy

Ulloa¹

2023

rebiol

View full text Add to dashboard Cite

The aim of this study was determine the frequency of low bone mineral density (BMD) in young men with asymptomatic Human Immunodeficiency Virus (HIV) infection on antiretroviral therapy for less than 2 years, as well as to compare the frequency of low and normal BMD according to antiretroviral treatment (ART) scheme and level of physical activity. 39 young men with asymptomatic HIV infection and ART less than 2 years were included. A bone densitometry was performed, and the following areas were evaluated: lumbar spine, left femoral neck and total left hip. 12 patients (31%) with low BMD and 27 patients (69%) with normal BMD were found. No differences were found between patients with normal and low BMD according to type of ART and level of physical activity. The frequency of low BMD is high in young men with asymptomatic HIV infection under antiretroviral treatment for less than 2 years.

show abstract

Low bone mass and vitamin D in Brazilian people living with HIV under antiretroviral therapy

et al. 2022

View full text Add to dashboard Cite

Osteopenia and osteoporosis among treatment-experienced people living with HIV

Cited by 6 publications

References 43 publications

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV

Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV

Low Bone Mineral Density in Young Men With Asymptomatic Human Immunodeficiency Virus Infection on Antiretroviral Therapy

Low bone mass and vitamin D in Brazilian people living with HIV under antiretroviral therapy

Contact Info

Product

Resources

About